Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG3 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Institut De Recherches Internationales Servier IRIS

Conditions

BRAF and Other Selected RAS/MAPK MutationsColorectal cancerHER2 positive resectable esophagogastric adenocarcinomaMalignancies with Documented KRAS

Phase 1

NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma

RecruitingCTIS2024-518841-12-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHHER2 positive resectable esophagogastric adenocarcinoma

Start: 2025-03-25Target: 39Updated: 2025-12-01

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Not yet recruitingCTIS2025-523474-16-00

Institut De Recherches Internationales Servier IRISBRAF and Other Selected RAS/MAPK Mutations, Malignancies with Documented KRAS

Target: 75Updated: 2026-04-22

Phase 2

FUTURE platform trial – A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities

RecruitingCTIS2024-517573-24-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHColorectal cancer

Start: 2025-12-08Target: 33Updated: 2025-12-02